HOME > TOP STORIES
TOP STORIES
-
BUSINESS Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
-
BUSINESS Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014
July 18, 2014
-
BUSINESS Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President
July 17, 2014
-
BUSINESS Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo
July 16, 2014
-
BUSINESS Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient
July 15, 2014
-
BUSINESS “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel
July 14, 2014
-
REGULATORY Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
-
BUSINESS Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016
July 11, 2014
-
BUSINESS Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
-
BUSINESS Bayer Yakuhin Sees Cancer Drugs as New Pillar
July 9, 2014
-
BUSINESS MTPC Aspires to Derive 30% of Sales from Offshore Biz
July 8, 2014
-
BUSINESS Sanofi to Bounce Back with New Portfolios, Shift to “Mabs”: Pres.
July 7, 2014
-
BUSINESS Sawai Preparing to File More Products for US Approval: Exec
July 4, 2014
-
REGULATORY MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
-
BUSINESS Meiji Seika Pharma Wants to Make Cancer Drugs, Biologics 4th Biz Pillar
July 3, 2014
-
BUSINESS Pfizer Japan to Diversify Revenue Streams to Maintain Growth in “Post-Lipitor Era”: President
July 2, 2014
-
REGULATORY Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
-
BUSINESS Sanofi, Takeda Team Up to Raise Awareness of Diabetes
July 1, 2014
-
BUSINESS Takeda CEO Counters Opposing Shareholders, Says Mr Weber Most Appropriate to Lead Drug Maker
June 30, 2014
-
BUSINESS Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…